||1R37CA226081-01 Interpret this number
||Evaluation of Genetic, Clinical, and Environmental Risk Factors to Establish Effective Screening Strategies for Second Primary Lung Cancer
Lung cancer (LC) is a leading cause of cancer deaths in the U.S. The widespread adoption of computed
tomography (CT) screening enables the early detection of lung cancer and is expected to increase the number
of long-term LC survivors. The estimated number of LC survivors is approximately 412,230 as of 2012 and is
projected to be over a half million in 2022. Recent studies show that LC survivors have a high risk of
developing second primary lung cancer (SPLC), the incidence of which is around 4-6 times higher than that of
initial primary lung cancer (IPLC) in the general population. While national lung screening guidelines have been
established for IPLC by the U.S. Preventive Services Task Force (USPSTF), no such consensus guidelines
exist for LC survivors who are exposed to a high risk of SPLC. Furthermore, the factors that contribute to the
development of SPLC have not yet been established. Our long-term goal is to reduce the overall LC mortality
in the U.S. population by focusing on SPLC. The overall objectives of this application are to identify the
genetic, clinical, and environmental determinants for SPLC, to assess an individual’s risk of developing SPLC,
and to evaluate efficient lung screening strategies for SPLC to help inform the development of consensus
screening guidelines for LC survivors. Our aims are: (AIM 1) To identify the genetic, environmental, clinical,
and demographic risk factors for SPLC and to develop a risk prediction model for SPLC. We will use cohort
data from the Transdisciplinary Research in Cancer of the Lung (TRICL) and the International Lung Cancer
Consortium (ILCCO) to evaluate risk factors for SPLC; (AIM 2) To evaluate optimal CT screening strategies
for SPLC by estimating the population-level harms and benefits of CT screening under various selection
criteria. We will develop a stochastic simulation model for SPLC that integrates the incidence, progression, and
survival of SPLC to quantify the population-level harms and benefits of screening for SPLC under various risk-
based selection criteria; (AIM 3) To estimate the lifetime costs and to assess the cost-effectiveness of CT
screening strategies for SPLC in the general U.S. population. The contribution of our research will be
significant because it will provide a better understanding of the etiology of SPLC by identifying various risk
factors for SPLC using comprehensive population-based data. Second, the completion of our research will
provide a valuable decision tool for evaluating an individual’s risk of developing SPLC, which can help identify
high-risk individuals for screening. Finally, by evaluating the potential harms and benefits of lung cancer
screening for SPLC under various criteria, our research will provide a set of optimal CT screening strategies,
the results of which will reduce clinicians’ uncertainty on how to best guide LC survivors for CT screening.
Disparities of national lung cancer screening guidelines in the U.S. population.
, Chow E.
, Ten Haaf K.
, Toumazis I.
, Cao P.
, Bastani M.
, Tammemagi M.
, Jeon J.
, Feuer E.
, Meza R.
, et al.
Journal of the National Cancer Institute, 2020-02-10; , .